BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Tuesday, April 23, 2024
Home
»
Newsletters
» BioWorld
BioWorld
July 17, 2007
View Archived Issues
Affymax Clearing Pathway For Hematide In 'Murky' ESA Space
In the midst of increased regulatory scrutiny involving erythropoiesis-stimulating agents (ESAs), Affymax Inc. is forging ahead with a Phase III program of its anemia drug, Hematide, in chronic renal failure patients. (BioWorld Today)
Read More
Novocell Gets $25 Million For Stem Cell Programs
Read More
Swiss Firm GlycoVaxyn Raises $9.5M For Vaccine Programs
Read More
Arpida's Iclaprim Wins Again In Phase III Study For cSSIs
Read More
Send In Your Stupid Biotech Ideas
Read More
Other News To Note
Read More
Clinic Roundup
Read More